Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized double-blind placebo-controlled trial of quinagolide dose titration in oocyte donors at risk of ovarian hyperstimulation syndrome
2008-000201-11Phase 2Active
- Sponsor
- IVI
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ovarian hyperstimulation syndrome (OHSS) comparing Quinagolide dose-titration with Placebo (2 arms). Primary endpoint: Tolerability of quinagolide 200 mcg/day in a dose-titration regimen. Started May 2008; status: active.
02
Drugs
quinagolide
03
Conditions
ovarian hyperstimulation syndrome (OHSS)
Beyond the preview
Go deeper on 2008-000201-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000201-11.